Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of Praluent after neurocognitive parent trial
2018-002810-11Phase 4Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Oct 2018; status: terminated.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on 2018-002810-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002810-11.